

Applies to:
Commercial Products

- ☒ Harvard Pilgrim Health Care Commercial products
☐ Tufts Health Plan Commercial products

Public Plans Products

- ☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)
☐ Tufts Health Together – MassHealth Accountable Care Partnership Plans
☐ Tufts Health RITogether – A Rhode Island Medicaid Plan
☐ Tufts Health One Care – A dual-eligible product

Senior Products

- ☐ Tufts Health Plan Senior Care Options (SCO) (a dual-eligible product)
☐ Tufts Medicare Preferred HMO/PPO (Medicare Advantage products)

Policy

Nucleic acid hybridization technologies utilize complementary properties of the DNA double-helix structures to anneal together DNA fragments from different sources. These techniques are utilized in polymerase chain reaction (PCR) and fluorescent resonance energy transfer (FRET) techniques to identify microorganisms.¹

A discussion of every infectious agent that might be detected with a probe technique is beyond the scope of this policy. Many probes have been combined into panels of tests. For the purposes of this policy, only individual probes are reviewed.

~~For guidance on nucleic acid identification of *Candida* in vaginitis, please refer to the Diagnosis of Vaginitis policy.~~

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- The coverage status of nucleic acid identification using direct probe, amplified probe, or quantification for the microorganism's procedure codes is summarized in Table 1 below. "MCC" in the table below indicates that the test **MEETS COVERAGE CRITERIA**; while "DNMCC" tests indicates that the test **DOES NOT MEET COVERAGE CRITERIA**.

Microorganism	Direct Probe	Amplified Probe	Quantification
<i>Bartonella henselae</i> or <i>quintana</i>		87471 (MCC)	87472 (DNMCC)
<i>Chlamydia pneumoniae</i>	87485 (DNMCC)	87486 (MCC)	87487 (DNMCC)
<i>Clostridium difficile</i>		87493 (MCC)	
<i>Cytomegalovirus</i>	87495 (DNMCC)	87496 (MCC)	87497 (MCC)
<i>Enterococcus</i> , Vancomycin-resistant (e.g., <i>enterococcus vanA</i> , <i>vanB</i>)		87500 (MCC)	
<i>Enterovirus</i>		87498 (MCC)	
Hepatitis G	87525 (DNMCC)	87526 (DNMCC)	87527 (DNMCC)
Herpes virus-6	87531 (DNMCC)	87532 (DNMCC)	87533 (MCC)
<i>Legionella pneumophila</i>	87540 (DNMCC)	87541 (MCC)	87542 (DNMCC)
<i>Orthopoxvirus</i>		87593 (MCC)	

<i>Mycoplasma pneumoniae</i>	87580 (DNMCC)	87581 (MCC)	87582 (DNMCC)
Respiratory syncytial virus		87634 (MCC)	
<u>Rubeola virus</u>		<u>87638 (MCC)</u>	
<i>Staphylococcus aureus</i>		87640 (MCC)	
<i>Staphylococcus aureus, methicillin resistant</i>		87641 (MCC)	

2. Simultaneous ordering of amplified probe and quantification for the same organism in a single encounter **DOES NOT MEET COVERAGE CRITERIA.**

Applicable CPT/HCPCS Procedure Codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Coding

Code	Description
87471	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique
87472	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, quantification
87485	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique
87486	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique
87487	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification
87493	Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique
87495	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique
87496	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, amplified probe technique
87497	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification
87498	Infectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed
87500	Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (e.g., enterococcus species van A, van B), amplified probe technique
87525	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, direct probe technique
87526	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, amplified probe technique
87527	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, quantification
87531	Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, direct probe technique
87532	Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, amplified probe technique
87533	Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, quantification
87540	Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, direct probe technique
87541	Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, amplified probe technique
87542	Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, quantification
87580	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, direct probe technique
87581	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique
87582	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, quantification
87593	Infectious agent detection by nucleic acid (DNA or RNA); orthopoxvirus (e.g., monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each
87634	Infectious agent detection by nucleic acid (DNA or RNA); respiratory syncytial virus, amplified probe technique
<u>87638</u>	<u>Infectious agent detection by nucleic acid (DNA or RNA); rubeola (measles) virus (effective for DOS beginning 12/01/2026)</u>
87640	Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, amplified probe technique
87641	Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified

Code	Description
	probe technique

Evidence-based Scientific References

1. Khan A. Rapid Advances in Nucleic Acid Technologies for Detection and Diagnostics of Pathogens. J Microbiol Exp. 2014;1(2)doi:10.15406/jmen.2014.01.00009
2. Mothershed EA, Whitney AM. Nucleic acid-based methods for the detection of bacterial pathogens: present and future considerations for the clinical laboratory. Clinica chimica acta; international journal of clinical chemistry. 2006;363(1-2):206-20. doi:10.1016/j.cccn.2005.05.050
3. WHO. Monkeypox. <https://www.who.int/news-room/fact-sheets/detail/mpox>
4. Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clinical Infectious Diseases. 2018;ciy381-ciy381. doi:10.1093/cid/ciy381
5. Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) *. Clinical Infectious Diseases. 2024;doi:10.1093/cid/ciae104
6. CDC. Laboratory Testing for Chlamydia pneumoniae. Updated September 17, 2025. <https://www.cdc.gov/cpnemoniae/php/laboratories>
7. CDC. Clinical Testing and Diagnosis for C. diff Infection. Updated March 6, 2024. <https://www.cdc.gov/c-diff/hcp/diagnosis-testing/>
8. CDC. Laboratory Testing for CMV and Congenital CMV. Updated April 15, 2024. <https://www.cdc.gov/cytomegalovirus/php/laboratories/index.html>
9. CDC. Laboratory Testing for Measles. Updated June 12, 2024. <https://www.cdc.gov/measles/php/laboratories/index.html>
10. CDC. Test Types Typically Available to Clinicians and Descriptions for Measles, Mumps, Rubella, and Varicella. Updated January 2025. https://www.cdc.gov/mumps/media/pdfs/2025/02/MMRV-Testing-for-Clinicians_Jan2025.pdf
11. CDC. Monkeypox Case Definitions. Updated January 30, 2026. <https://www.cdc.gov/monkeypox/php/case-definitions/index.html>
12. CDC. Diagnostic Testing for Monkeypox. Updated February 6, 2026. <https://www.cdc.gov/mpox/hcp/diagnosis-testing/>
13. CDC. Laboratory Testing for Methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA). Updated June 27, 2025. <https://www.cdc.gov/mrsa/php/laboratories/index.html>
14. CDC. Laboratory Testing for Mycoplasma pneumoniae. Updated May 18, 2026. <https://www.cdc.gov/mycoplasma/php/laboratories>
15. CDC. Laboratory Testing for Non-Polio Enterovirus. Updated April 16, 2024. <https://www.cdc.gov/non-polio-enterovirus/php/laboratories/index.html>
16. CDC. Diagnostic Testing for RSV. Updated February 24, 2026. <https://www.cdc.gov/rsv/hcp/clinical-overview/diagnostic-testing.html>
17. CDC. Laboratory Testing for Legionella. Updated May 13, 2026. <https://www.cdc.gov/legionella/php/laboratories>
18. CDC. About Bartonella. Updated March 23, 2026. <https://www.cdc.gov/bartonella/about/>
19. ECDC. Risk assessment: Monkeypox multi-country outbreak. 2022. <https://www.ecdc.europa.eu/en/publications-data/risk-assessment-monkeypox-multi-country-outbreak>
20. ECDC. Interim advice on Risk Communication and Community Engagement during the monkeypox outbreak in Europe, 2022. 2022. <https://www.ecdc.europa.eu/sites/default/files/documents/Joint-ECDC-WHO-interim-advice-on-RCCE-for-Monkeypox-2-June-2022.pdf>
21. UKHSA. Monkeypox: diagnostic testing. <https://www.gov.uk/guidance/monkeypox-diagnostic-testing>
22. HHV-6 Foundation. Overview on Testing for HHV-6 infection. <https://hhv-6foundation.org/patients/hhv-6-testing-for-patients>
23. Public Health Ontario. Mycology – Pneumocystis jirovecii pneumonia (PJP) Detection. <https://www.publichealthontario.ca/en/laboratory-services/test-information-index/pneumocystis-jirovecii>
24. NIH/HIVMA/IDSA. Pneumocystis Pneumonia. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis>
25. Dockrell D, Breen R, Collini P, Lipman M, Miller R. British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of pulmonary opportunistic infections 2024 <https://www.bhiva.org/wp-content/uploads/2024/10/OI-guidelines-Pulmonary.pdf>

Publication History

12/01/2026: Annual policy review: administrative edits; added CPT code 87638, effective for DOS beginning Dec. 1, 2026

09/01/2025: Policy created to support coverage guidelines, effective for dates of service beginning Nov. 1, 2025

Background and Disclaimer Information

This policy applies to the products of Harvard Pilgrim Health Care and Tufts Health Plan and their affiliates, as identified in the check boxes on the first page for services performed by contracted providers.

Payment is based on member benefits and eligibility on the date of service, medical necessity review, where applicable, and the provider's network participation agreement with the Plan. As every claim is unique, this policy is neither a guarantee of payment, nor a final indication of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management requirements (when applicable), adherence to Plan policies and procedures, and claims editing logic. An authorization is not a guarantee of payment.

Point32Health reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated as applicable; please adhere to the most recent CPT and HCPCS coding guidelines.

We reserve the right to conduct audits on any provider and/or facility to ensure accuracy and compliance with the guidelines stated in this payment policy. If such an audit determines that a provider/facility did not comply with this payment policy, Harvard Pilgrim Health Care and Tufts Health Plan will expect the provider/facility to refund all payments related to noncompliance.